Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Every year, we hold a STAT Madness tournament to find the best ...

“I do believe the Chinese biotech industry will play an important ... is driven by a deep understanding of disease biology and protein engineering, while benefitting from the fast development ...

Ori Biotech's Preferred Partner Network was created to help deliver solutions that speed time to the clinic and shorten development timelines.

Privately-held Swedish firm Salipro Biotech AB, a specialist in the stabilization of challenging drug targets, today ...

Micreos Pharmaceuticals AG (”Micreos”), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease ...

The collaboration combines Salipro Biotech’s unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim’s drug discovery programs to enable ...

STOCKHOLM, March 13, 2025 (GLOBE NEWSWIRE) -- Salipro Biotech AB, a Swedish biotech ... of new therapeutic solutions targeting G protein-coupled receptors (GPCRs), ion channels, transporters ...